Table 1.

Time of measurement for each end point and associated measurements.

End point	Baseline measurement	Day of treatment measurement	Follow-up measurement
Real-life application of radioembolization	Type of liver cancer Prior hepatic procedures Associated systemic therapy (prior systemic therapy)	Intention of treatment	Postradioembolization hepatic procedures Postradioembolization systemic chemotherapy
Effectiveness end points	N/Aa	Treatment date	Date of effectiveness event (OSb, PFSc, hepatic PFS, IRd)
Safety end points	N/A	Severe day of treatment complications (Grade 3-4)e	Adverse events (Grade 1-5)e Abnormal laboratory values
Technical considerations end points	Patient-related characteristics Prior hepatic procedures Physical characteristics (body surface area, lung shunt study [%], Eastern Cooperative Oncology Group performance status)	Treatment planning Treatment administration Procedure-related outcomes	N/A
Patient-reported outcome end points	EORTCf QLQ-C30g Additional module for HCCh	N/A	EORTC QLQ-C30 Additional module for HCC

^aN/A: not applicable.

^bOS: overall survival.

^cPFS: progression-free survival.

^dIR: imaging response.

^eGrading according to Common Terminology Criteria for Adverse Events version 4.03.

^fEORTC: European Organisation for the Research and Treatment of Cancer.

^gQLQ-C30: Quality of Life Questionnaire C30.

^hHCC: hepatocellular carcinoma.